WHAT IS CLAIMED IS:

1. A method for creating a population of T cells with a desired native antigen specificity, the method comprising:

A. adding PBMCs or cord blood into a cell culture device,

B. adding media and more than one antigen into said cell culture device in order to activate the growth of more than one population of antigen specific T cells, each antigen specific T cell population having native antigen specificity to one of said antigens,

C. allowing a period of time for at least one said antigen specific T cell population to initiate population expansion in response to at least one of said antigens,

D. assessing the culture to determine the presence and/or quantity of at least one antigen specific T cell population,

E. determining which of the antigen specific T cell populations is suitable for continued proliferation, and

F. re-stimulating the culture with antigens only recognized by the antigen specific T cell population(s) deemed suitable for continued proliferation.

2. The method of claim 1 wherein the outcome of the process creates a single antigen specific T cell population.

3. The method of claim 1 wherein said antigen specific T cell population(s) suitable for continued proliferation include native antigen specificity that is only able to recognize antigens that that are not present on normal cells.

4. The method of claim 1 wherein said antigen specific T cell population(s) suitable for continued proliferation include native antigen specificity that is only able to recognize antigens that that are not present on normal human cells.

5. The method of claim 4 wherein said antigen specific T cell population(s) suitable for continued proliferation include native antigen specificity that is only able to recognize a single epitope of antigens that are not present on normal human cells.

6. The method of claim 3 wherein antigen specific T cell population(s) suitable for continued proliferation include native antigen specificity that is only capable of recognizing antigens that that are not present on normal cells and are capable of recognizing antigens including those of reptiles, amphibians, fish, birds, invertebrates, bacteria, fungus, parasites, sponges, and/or virus.

7. The method of claim 1 wherein said cell culture device includes gas permeable material.

8. The method of claim 7 wherein said PBMCs or cord blood reside upon said gas permeable material.

9. The method of claim 1 wherein said the distance between the lowest level of said media the highest level of said media resides exceeds 2.0 cm.

10. The method of claim 1 wherein said PBMC or cord blood resides at a surface density of less than 500,000 cm^2.

11. (New) A method for creating a population of T cells with a desired native antigen specificity, the method comprising:

A. adding PBMCs or cord blood into a cell culture device,

B. adding media and antigen into said cell culture device in order to activate the growth of antigen specific T cells having native antigen specificity to said antigen,

C. the distance between the lowest level of said media the highest level of said media resides exceeding 2.0 cm,

D. said PBMCs or cord blood residing upon gas permeable material,

E. said native antigen specificity only capable of recognizing antigens that that are not present on normal cells.

12. The method of claim 11 wherein said antigen specific T cells have native antigen specificity that is only able to recognize antigens that that are not present on normal human cells.

13. The method of claim 12 wherein said antigen specific T cells have native antigen specificity that is only able to recognize a single epitope of antigens that are not present on normal human cells.

14. The method of claim 12 wherein said antigen specific T cells have native antigen specificity that is only capable of recognizing antigens that that are not present on normal cells

and are at least capable of recognizing antigens including those of reptiles, amphibians, fish, birds, invertebrates, bacteria, fungus, parasites, sponges, or virus.

15. The method of claim 11 wherein said PBMCs or cord blood reside at a surface density of less than 500,000 cells per cm^2.

WHAT IS CLAIMED IS

1. A T-Vehicle comprising:

a human T cell that has been obtained from a healthy donor and has a native T cell receptor and has been modified to include a therapeutic attribute and the only antigen the modified T cell is able to recognize is a non-human antigen.

2. The T-Vehicle of claim 1 where the therapeutic attribute includes a chemotherapeutic agent.

3. The T-Vehicle of claim 1 where the therapeutic attribute includes a antimicrobial agent.

4. The T-Vehicle of claim 1 where the therapeutic attribute includes a radio isotope.

5. The T-Vehicle of claim 1 where the therapeutic attribute includes DNA.

6. The T-Vehicle of claim 1 where the therapeutic attribute includes RNA.

7. The T-Vehicle of claim 1 where the therapeutic attribute includes a recombinant protein.

8. The T-Vehicle of claim 1 where the therapeutic attribute includes a peptide.

9. The T-Vehicle of claim 1 where the therapeutic attribute includes an aptamer.

10. The T-Vehicle of claim 1 where in the T-Vehicle is frozen.

11. The T-Vehicle of claim 1 where the T-Vehicle is stored in an allogeneic cell bank.

12. A T-Vehicle comprising:

a human T cell with a native T cell receptor that only recognizes a non-human antigen and the T cell has been modified to make the T cell a transport vehicle that can deliver a

therapeutic attribute comprising a chemotherapeutic agent, antimicrobial agent, radio isotope, DNA, RNA, recombinant protein, peptide, or aptamer.

13. The T-Vehicle of claim 12 where the human T cell is obtained from a healthy donor.

14. The T-Vehicle of claim 12 where the T-Vehicle is frozen.

15. A T-Vehicle comprising:

a T cell that includes a native T cell receptor that only recognizes antigens that are not present on normal human cells and has been modified to include a therapeutic attribute and is frozen and stored in an allogeneic cell bank.